(PRWEB) February 4, 2008
Biotechnology companies from across the UK, Europe and North America will partner with the best of hundreds of companies in the Oxford & South East BioCluster at BioTrinity 2008 -- Oxford. Companies in the Oxford BioCluster alone having completed financings worth over £324m since 2005*, with the total value of M&A deals being £530m, a total of over 1.13bn Euro.
The conference organisers (OBN) took inspiration from Stephen G Burrill and will publish in depth details of every financing and deal struck by biotechs in the Oxford biocluster since 2005 in the comprehensive OBN BioCluster Report 2008, which will be launched at BioTrinity 2008.
BioTrinity 2008 - Oxford works by bringing together key players and decision makers from the biotech industry, featuring a gold-standard one-to-one partnering service with the unusual offer of private partnering rooms as standard. There are also company showcase presentations of the 25 most promising emerging companies and companies with compounds in clinical trials from the region, venture capital and licensing panel discussions, and a showcase of young spin-out technology companies.
BioTrinity is the place to be if you want to meet with the hottest biotechs from the Oxford region, a view confirmed by Venture Capitalist David Mott, the Investment Director and co-founder of Oxford Capital Partners:
"...the conference was a great success. There was a high calibre of participants and the event has raised the profile the Oxford and Thames Valley biotech cluster. This will create a rising tide for us all."
(read more http://www.biotrinity.com/testimonials.html)
BioTrinity 2008 has been positioned as the Oxford & South-East BioCluster's equivalent of the ERBI Bioexchange and London's Genesis conferences. What the organisers of BioTrinity 2008 have done with an innovative business model allows access to SME biotechs, providing a summit and networking venue for small and medium sized companies to meet pharma, investors, innovators, scouts and tech transfer agents.
"BioTrinity is very productive: last year we catered for over 500 partnering meetings, over 400 delegates from nearly 300 companies, with over 180 licensing opportunities in its inaugural year, and this year we've increased our capacity and expect to host over 800 partnering meetings all in private partnering rooms," said Jon Rees PhD, OBN's Network Director, commenting, "We aim to deliver a meeting of international quality, with international participation within a region context".
BioTrinity 2008 speakers include:
- Atlas Venture (Life Sciences Principal)
- Shire Pharma (Director of Business Development)
- BMS (Director of Licensing, Europe)
- Merck (Director Scientific Liaison)
- Genzyme (VP and GM)
- Evotec UK Limited (EVP, Business Development)
- (OSI) Prosidion, President
- Summit plc (CEO)
- Glide Pharma (CEO)
- Chemocentryx (CEO)
- Celleron Therapeutics (CEO)
- Hybrid Systems (CEO)
- Oxford Capital Partners (Co-founder and Investment Director)
- Solace Pharma (CEO)
The organisers say they expect over 300 companies to attend BioTrinity 2008 - Oxford, and if the delegate list is anywhere near as impressive as the CEO-laden speaker list, BioTrinity will be the place to partner with biotechs in the UK in Spring 2008.
BioTrinity 2008, 15-16 April 2008, Oxford, is the country's leading biotech networking event. It will showcase the Southern UK's biotechnology super cluster, which leads the UK in attracting investment. Twenty-five of the most promising drug discovery and development, diagnostics and medical device companies have been selected to be featured in BioTrinity's "Most Promising Emerging Company Showcase" and "Clinical Stage Developments" featuring the region's drug pipeline. There are also: one-to-one partnering meetings, a licensing and spin-out technology showcase, an exhibition and a number of workshops. More conference details are available online at http://www.biotrinity.com
OBN is the South East's leading biotech business network, catalysing the growth and development of the Oxford and the South East biotech and healthcare biotech super-cluster. Launched by Lord Sainsbury in 1999, OBN is a financially self-sustainable network which raises 99% of its operating costs from private sources and operational activity, as well as membership. In the past 8 years, OBN has delivered over 90 meetings, attracting thousands of delegates, most notably its trademark BioTuesday biotech business networking evenings and BioTrinity, its annual partnering conference. More information is available online at http://www.oxfordshirebioscience.net